By Emma Pinedo MADRID (Reuters) – Spanish drugmaker Almirall, which is building up its business in skin treatments, could be interested in acquiring dermatology assets from Canada's Valeant Pharmaceuticals, the head of the Barcelona-based company said on Monday. Valeant is looking at divesting various products as it tries to reduce its massive debt load, with new CEO Joe Papa open to selling a range of assets if the price is right. Almirall Chief Executive Eduardo Sanchiz is leading a period of significant change at the company, following a shake-up of its drug portfolio, and building up the dermatology business further would fit with the Spanish group's strategy.
More here:
Spain’s Almirall eyes Valeant skin drugs to boost dermatology
